Israel - English - Ministry of Health

zoetis israel holding b.v., israel - cefovicin as sodium salt - powder and solvent for solution for injection - cefovicin as sodium salt 80 mg/dose - dogs : for the treatment of skin and soft tissue infections including pyoderma wounds and abscesses associated with staphylococcus intermedius beta-haemolytic streptococci escherichia coli and/or pasteurella multocida. for the treatment of urinary tract infections associated with escherichia coli and/or proteus spp.as adjunctive treatment to mechanical or surgical periodontal therapy of severe infections of the gingival and periodontal tissues associated with porphyromonas spp. and prevotella spp. cats : for the treatment of skin and soft tissue abscesses and wounds associated with pasteurella multocida fusobacterium spp. bacteroides spp. prevotella oralis beta-haemolytic streptococci and/or staphylococcus intermedius. for the treatment of urinary tract infections associated with escherichia coli.

Israel - English - Ministry of Health

pfizer pharmaceuticals israel ltd - cefovicin as sodium salt 80 mg/dose - powder for solution for injection - dogs : for the treatment of skin and soft tissue infections including pyoderma wounds and abscesses associated with staphylococcus intermedius beta-haemolytic streptococci escherichia coli and/or pasteurella multocida. for the treatment of urinary tract infections associated with escherichia coli and/or proteus spp. as adjunctive treatment to mechanical or surgical periodontal therapy of severe infections of the gingival and periodontal tissues associated with porphyromonas spp. and prevotella spp.cats : for the treatment of skin and soft tissue abscesses and wounds associated with pasteurella multocida fusobacterium spp. bacteroides spp. prevotella oralis beta-haemolytic streptococci and/or staphylococcus intermedius. for the treatment of urinary tract infections associated with escherichia coli.

Israel - English - Ministry of Health

salomon,levin & elstein ltd - cefonicide as sodium - powder for solution for injection - cefonicide as sodium 1000 mg/vial - cefonicide - cefonicide - treatment of serious bacterial infections caused by microorganisms susceptible to cefonicid. studies on specimens obtained prior to therapy should be used to determine the susceptibility or the causative organisms to cefonicid.therapy with cefonicid may be initiated pending results of the studies however.treatment should be adjusted according to study findings. cefonicid-teva is indicated in the treatment of the infections of the lower respiratory tract urinary tract skin and skin structure bone and joints. in the treatment of the above-mentioned infections the product is particularly used in weak and/or immuno-depressed patients. surgical prophylaxis: the administration of a single 1 g. dose of cefonicid-teva before surgery may reduce the incidence of post-operative infections caused by susceptible microorganisms in patients undergoing surgical procedures classified as contaminated or potentially contaminated or in patients in whom infection at the operative site would present a serious risk providi

United States - English - NLM (National Library of Medicine)

wg critical care, llc - cefoxitin sodium (unii: q68050h03t) (cefoxitin - unii:6oev9dx57y) - cefoxitin 1 g - treatment cefoxitin for injection, usp is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) lower respiratory tract infections , including pneumonia and lung abscess, caused by streptococcus pneumoniae, other streptococci (excluding enterococci, e.g., enterococcus faecalis [formerly streptococcus faecalis]), staphylococcus aureus (including penicillinase-producing strains), escherichia coli, klebsiella species, haemophilus influenzae, and bacteroides species. (2) urinary tract infections caused by escherichia coli, klebsiella species, proteus mirabilis, morganella morganii, proteus vulgaris and providencia species (including p. rettgeri ). (3) intra-abdominal infections , including peritonitis and intra-abdominal abscess, caused by escherichia coli, klebsiella species, bacteroides species including bacteroides fragilis, and clostridium species. (4) gynecological infections , including endometritis,

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - cefoxitin sodium (unii: q68050h03t) (cefoxitin - unii:6oev9dx57y) - cefoxitin 10 g - treatment cefoxitin for injection, usp is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1)     lower respiratory tract infections ,   including pneumonia and lung abscess, caused by streptococcus pneumoniae , other streptococci (excluding enterococci, e.g., enterococcus faecalis [formerly streptococcus faecalis ]), staphylococcus aureus (including penicillinase-producing strains), escherichia coli, klebsiella species, haemophilus influenzae, and bacteroides species. (2)     urinary tract infections   caused by escherichia coli, klebsiella species, proteus mirabilis, morganella morganii, proteus vulgaris and providencia species (including p. rettgeri ). (3)     intra-abdominal infections , including peritonitis and intra-abdominal abscess, caused by escherichia coli, klebsiella species, bacteroides species including bacteroides fragilis , and clostridium species. (4)     gynecological infections ,

United States - English - NLM (National Library of Medicine)

wg critical care, llc - cefoxitin sodium (unii: q68050h03t) (cefoxitin - unii:6oev9dx57y) - cefoxitin 1 g - treatment cefoxitin for injection, usp is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) lower respiratory tract infections , including pneumonia and lung abscess, caused by streptococcus pneumoniae, other streptococci (excluding enterococci, e.g., enterococcus faecalis [formerly streptococcus faecalis]), staphylococcus aureus (including penicillinase-producing strains), escherichia coli, klebsiella species, haemophilus influenzae, and bacteroides species. (2) urinary tract infections caused by escherichia coli, klebsiella species, proteus mirabilis, morganella morganii, proteus vulgaris and providencia species (including p. rettgeri ). (3) intra-abdominal infections , including peritonitis and intra-abdominal abscess, caused by escherichia coli, klebsiella species, bacteroides species including bacteroides fragilis, and clostridium species. (4) gynecological infections , including endometritis,

United States - English - NLM (National Library of Medicine)

samson medical technologies llc - cefoxitin sodium (unii: q68050h03t) (cefoxitin - unii:6oev9dx57y) - cefoxitin 100 g - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefoxitin and other antibacterial drugs, cefoxitin for injection, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefoxitin for injection, usp is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. - lower respiratory tract infections, including pneumonia and lung abscess, caused by streptococcus pneumoniae , other streptococci (excluding enterococci, e.g., enterococcus faecalis [formerly streptococcus faecalis ]), staphylococcus aureus (including penicillinase-producing strains), escherichia

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - cefoxitin sodium (unii: q68050h03t) (cefoxitin - unii:6oev9dx57y) - cefoxitin 1 g - cefoxitin for injection, usp is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) lower respiratory tract infections , including pneumonia and lung abscess, caused by streptococcus pneumoniae , other streptococci (excluding enterococci, e.g., enterococcus faecalis [formerly streptococcus faecalis ]), staphylococcus aureus (including penicillinase-producing strains), escherichia coli, klebsiella species, haemophilus influenzae, and bacteroides species. (2) urinary tract infections caused by escherichia coli, klebsiella species, proteus mirabilis, morganella morganii, proteus vulgaris and providencia species (including p. rettgeri ). (3) intra-abdominal infections , including peritonitis and intra-abdominal abscess, caused by escherichia coli, klebsiella species, bacteroides species including bacteroides fragilis , and clostridium species. (4) gynecological infections , including endometritis, pelvi

United States - English - NLM (National Library of Medicine)

apotex corporation - cefoxitin sodium (unii: q68050h03t) (cefoxitin - unii:6oev9dx57y) - cefoxitin 1 g - treatment many infections caused by aerobic and anaerobic gram-negative bacteria resistant to some cephalosporins respond to cefoxitin. similarly, many infections caused by aerobic and anaerobic bacteria resistant to some penicillin antibiotics (ampicillin, carbenicillin, penicillin g) respond to treatment with cefoxitin. many infections caused by mixtures of susceptible aerobic and anaerobic bacteria respond to treatment with cefoxitin. cefoxitin for injection is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) lower respiratory tract infections , including pneumonia and lung abscess, caused by streptococcus pneumoniae , other streptococci (excluding enterococci, e.g., enterococcus faecalis [formerly streptococcus faecalis ]), staphylococcus aureus  (including penicillinase-producing strains), escherichia coli ,  klebsiella species, haemophilus influenzae ,  and bacteroides species. (2) urinary tract i

United States - English - NLM (National Library of Medicine)

sagent pharmaceuticals - cefoxitin sodium (unii: q68050h03t) (cefoxitin - unii:6oev9dx57y) - cefoxitin 1 g - cefoxitin for injection, usp is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) lower respiratory tract infections, including pneumonia and lung abscess, caused by streptococcus pneumoniae , other streptococci (excluding enterococci, e.g., enterococcus faecalis [formerly streptococcus faecalis ]), staphylococcus aureus (including penicillinase-producing strains), escherichia coli , klebsiella species, haemophilus influenzae, and bacteroides species. (2) urinary tract infections caused by escherichia coli , klebsiella species, proteus mirabilis , morganella morganii , proteus vulgaris and providencia species (including p. rettgeri ). (3) intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by escherichia coli , klebsiella species, bacteroides species including bacteroides fragilis , and clostridium species. (4) gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by escherichia coli , neisseria gonorrhoeae (including penicillinase-producing strains), bacteroides species including b. fragilis , clostridium species, peptococcus niger , peptostreptococcus species, and streptococcus agalactiae . cefoxitin for injection, usp, like cephalosporins, has no activity against chlamydia trachomatis . therefore, when cefoxitin for injection, usp is used in the treatment of patients with pelvic inflammatory disease and c. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) septicemia caused by streptococcus pneumoniae , staphylococcus aureus (including penicillinase-producing strains), escherichia coli , klebsiella species, and bacteroides species including b. fragilis. (6) bone and joint infections caused by staphylococcus aureus (including penicillinase-producing strains). (7) skin and skin structure infections caused by staphylococcus aureus (including penicillinase-producing strains), staphylococcus epidermidis , streptococcus pyogenes and other streptococci (excluding enterococci e.g., enterococcus faecalis [formerly streptococcus faecalis ]), escherichia coli , proteus mirabilis , klebsiella species, bacteroides species including b. fragilis , clostridium species, peptococcus niger , and peptostreptococcus species. appropriate culture and susceptibility studies should be performed to determine the susceptibility of the causative organisms to cefoxitin for injection, usp. therapy may be started while awaiting the results of these studies. in randomized comparative studies, cefoxitin for injection, usp and cephalothin were comparably safe and effective in the management of infections caused by gram-positive cocci and gram-negative rods susceptible to the cephalosporins. cefoxitin for injection, usp has a high degree of stability in the presence of bacterial beta-lactamases, both penicillinases and cephalosporinases. many infections caused by aerobic and anaerobic gram-negative bacteria resistant to some cephalosporins respond to cefoxitin for injection, usp. similarly, many infections caused by aerobic and anaerobic bacteria resistant to some penicillin antibiotics (ampicillin, carbenicillin, penicillin g) respond to treatment with cefoxitin for injection, usp. many infections caused by mixtures of susceptible aerobic and anaerobic bacteria respond to treatment with cefoxitin for injection, usp. cefoxitin for injection, usp is indicated for the prophylaxis of infection in patients undergoing uncontaminated gastrointestinal surgery, vaginal hysterectomy, abdominal hysterectomy, or cesarean section. if there are signs of infection, specimens for culture should be obtained for identification of the causative organism so that appropriate treatment may be instituted. to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefoxitin for injection, usp and other antibacterial drugs, cefoxitin for injection, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefoxitin for injection is contraindicated in patients who have shown hypersensitivity to cefoxitin and the cephalosporin group of antibiotics.